SIGA SIGA Technologies Inc Total Asset Value of Company

SIGA (SIGA Corp) - company brandmark

SIGA Technologies, Inc. (SIGA) generates revenue by selling countermeasures against deadly viruses, supplying them to government stockpiles for pandemic response. Financial stability relies on TPOXX, creating a dangerous single-product dependency that the company mitigates through exports. This chart of the market price on GURU.Markets captures total assets at 205.15, confirming a debt-free balance sheet and an increase in NATO government orders.

SIGA (SIGA Technologies, Inc.) Company Total Assets history from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company SIGA Corp (SIGA)

- market value and analyst target forecast:
Stock Price siga.com|SIGA - Price Target Chart
- market capitalization data:
Market Valuation TPOXX|SIGA - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share SIGA Technologies|SIGA - Book Capitalization|Market Capitalization to Book Value Ratio siga.com|SIGA - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio SIGA Technologies, Inc.|SIGA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio TPOXX|SIGA - Company Aggregate Debts|Debts to Book Capitalization TPOXX|SIGA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings SIGA Technologies|Quick Liquidity siga.com
- net income and valuation multiples indicators:
SIGA - Net Profit
Fundamental valuation:SIGA Technologies, Inc.
Manufactured products of SIGA Technologies, Inc.

To identify fundamentally stable companies, investors analyze the total mass of controlled resources, which in this case is reverse-calculated via return on assets (ROA) by combining equity and liabilities. Since SIGA Technologies, Inc. (SIGA) outsources drug synthesis to third-party CMOs, the trajectory of total assets (via ROA) demonstrates capital management efficiency despite a high dependence on external production and strict medical compliance.

Key competitors

gilead.com (GILD) - Company Total Assets|Aggregate Company Assets cidara.com|Novavax Inc - Total Asset Value of Company|Company Total Assets CVAC|VALN (Valneva Vaccines) - Aggregate Asset Value|Company Total Assets VIR (Vir Biotechnology, Inc.)|Company Total Assets emergentbiosolutions.com EBS|AVIR - Aggregate Company Assets|Aggregate Asset Value IVVD (Invivyd, Inc.)|Enanta (ENTA) - Aggregate Company Assets|Cumulative Company Assets Inovio Pharma|HLVX (HilleVax, Inc.) - Company Total Assets|Company Total Assets kalaristx.com|Cumulative Company Assets DYAI (Dyadic International)|NNVC (nanoviricides.com) - Aggregate Asset Value|Talphera Corp - Cumulative Company Assets|Cocrystal Pharma Corp - Aggregate Company Assets|Traws Therapeutics - Company Total Assets|Company Total Asset Base Dogwood Therapeutics, Inc. DWTX|Qualigen Therapeutics, Inc. (QLGN) - Aggregate Company Assets|AlloVir - Aggregate Asset Value|Cumulative Company Assets VBIV|Company Total Assets Virios|Aggregate Company Assets Vaxart, Inc. (VXRT)